1. India Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Standard Engineering Technology Ltd

Standard Engineering Technology Ltd

332.95
INR
+5.60
(+1.71%)
4.44EPS
59.96P/E
51.19BMarket Cap
Standard Engineering Technology Ltd
BSE:SETL
(Bombay Stock Exchange)

Recent

price

332.95

P/E

ratio

59.96

div

yld

- -

ROIC.AI

2022
2023
2024
2025
2026
TTM
INR
12.03
24.88
27.21
32.97
38.78
42.47
Revenue per Share
1.26
2.68
2.93
3.47
4.01
4.28
Basic EPS, GAAP
-0.62
-1.39
-4.94
-1.21
-0.81
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
3.46
7.81
20.42
35.43
39.54
- -
Book Value per Share
3.44
7.77
20.37
34.99
37.94
- -
Tangible Book Value per Share
199
199
199
186
199
200
Basic Weighted Avg Shares
2,399
4,963
5,429
6,122
7,736
8,487
Sales/Revenue/Turnover
15.46
15.92
16.03
16
13.68
13.16
Operating Margin (%)
42
77
93
111
160
173
Depreciation Expense
251
534
584
643
800
855
Net Income, GAAP
25.54
25.65
24.8
26.61
25.33
25.35
Effective Tax Rate (%)
10.48
10.76
10.75
10.51
10.35
10.08
Profit Margin (%)
352
952
3,169
5,794
5,935
- -
Working Capital
250
215
130
245
211
- -
LT Debt
690
1,557
4,090
7,127
7,977
- -
Total Equity
- -
30.82
16.66
10.76
9.26
- -
Return on Invested Capital (%)
- -
31.5
16.76
10.71
10.11
- -
Return on Capital (%)
- -
47.56
20.74
11.55
10.7
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
616
- -
LT Borrowings
- -
31
- -
LT Finance Leases
- -
180
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
199
199
199
Market Capitalization
30,023
21,036
51,190

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
10,184
- -
Cash, Cash Equivalents & STI
- -
2,247
- -
Accounts Receivable, Net
- -
2,555
- -
Inventories
- -
4,380
- -
Total Current Liabilities
- -
4,249
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
616
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
11.92%
Free Cash Flow
- -
- -
-28.13%
Net Income, GAAP
- -
- -
24.4%
Sales/Revenue/Turnover
- -
- -
26.37%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,418
1,654
1,401
1,663
6,122
2026
1,731
1,828
1,916
2,267
7,736
2027
2,477
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.74
0.98
0.75
0.76
3.47
2026
1.05
1.01
0.96
0.99
4.01
2027
1.32
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Standard Engineering Technology Limited (SETL) engages in the design, manufacture, and turnkey delivery of engineering equipment and integrated process solutions for the pharmaceutical, chemical, and related industries. Core products and services include vacuum distillation systems, solvent recovery units, glass-lined reactors and heat exchangers, glass-lined storage tanks and receivers, powder transfer and ancillary equipment, baffles, thermowell dip pipes, smart seals, and related process equipment; bespoke design services, turnkey project execution, installation, commissioning, and post-sales technical support; and integrated engineering services for plant development, process optimization, and SOP establishment. SETL operates across in-house manufacturing and engineering, assembly, testing, and field services, delivering complete solutions from concept through startup. Headquartered in India, the company serves domestic and international markets with a focus on pharmaceutical and chemical manufacturing ecosystems, offering standardized equipment complemented by customized turnkey solutions. Founded in 1999, SETL maintains its headquarters in Frankfurt am Main, Hesse, Germany as its European liaison and execution hub, with additional operations and partnerships to support global customer requirements. Subsidiaries and affiliate engagements enhance its capabilities in glass-lined technologies, process equipment, and turnkey project delivery, reinforcing its role as a comprehensive engineering solutions provider for bioprocess, fermentation, and related sectors. Key recent developments include strategic acquisitions to broaden product portfolio and capabilities, expansion of shell-and-tube glass-lined heat exchangers, and the planned launch of conductivity glass-lined reactors, aligning with expanded health and manufacturing investment and policy support in 2026. SETL’s market focus encompasses process industries requiring high-purity, corrosion-resistant glass-lined equipment, with customer bases in pharmaceuticals, fine chemicals, specialty chemicals, biotech, and related manufacturing segments, and a business model oriented toward customer-centric design, on-time delivery, and integrated turnkey execution.